REPORT

11th ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY
**Chairs:** N. Pavlidis, GR - R. A. Stahel, CH
**Scientific Coordinators:** W. Gatzemeier, IT - R. Popescu, CH

5th ESO-EONS NURSING ONCOLOGY MASTERCLASS
**Chairs:** A. Margulies, CH - S. Faithfull, UK
**Scientific Coordinators:** L. Sharp, SE

17-22 March 2012
Ermatingen (Lake Constance), Switzerland

The Masterclass was held for the fourth time as a joint venture with ESMO, the European Society for Medical Oncology, for the fifth time with EONS the European Oncology Nursing Society, and for the first time as part of the Master-Online Study Program in Advanced Oncology of the University of Ulm.

**AIMS AND OBJECTIVES**

This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme exposed participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focused on breast, gastro-intestinal, genito-urinary, gynaecological, head and neck and lung cancers. Spotlight sessions facilitated compact update on haematological diseases, therapeutic management of gliomas, cancer and pregnancy, side effects of systemic treatment, oral therapy, palliative care, cancer of unknown primary, sarcoma, and treatment of melanoma.
TEACHING FORMAT
The Masterclass offered plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which concluded in take-home messages. The Clinical Sessions were complemented by Tumour Board discussions. Furthermore, participants delivered case presentations within small groups and discussed these with the chairmen and the faculty. All participants resided at the course venue and participation was compulsory throughout the course. The Masterclass was entirely in English and fluency in English was necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology attended selected medical sessions whilst the side effects, oral therapy and palliative care sessions were attended jointly.

THE MASTERCLASS IS:
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.

CME ACCREDITATION
The Accreditation Council for Oncology in Europe (ACOE) has recommended that the event be granted 27 European CME credits. The Masterclass has been furthermore accredited with 25 Category 1 ESMO MORA points.

ACKNOWLEDGEMENTS
ESO wishes to express its appreciation to Union Bank of Switzerland (UBS) and Wolfsberg Centre for their consideration and support to the 2012 Masterclass.

The Masterclass is part of the Sharing Progress in Cancer Care (SPCC) programme whose sustaining members are:

- Platinum members: Amgen and Eisai
- Gold members: Eli Lilly, GlaxoSmithKline Oncology, Merck Serono, Roche
- Silver members: Celgene Corporation, Genomic Health, Novartis Oncology and Sanofi Oncology

ESO thanks the Flims Alumni Club for the collaboration in promoting the Masterclass.
PROGRAMME:

17 March

14:30 Clinical session Genito-urinary cancers I
Chair: K. Fizazi, FR

Prostate cancer:

- Local therapy: Surgery and radiotherapy
  A. Horwich, UK
- First-line endocrine treatment
  A. Horwich, UK
- Endocrine resistant - refractory
  K. Fizazi, FR

16:10 Clinical session Genito-urinary cancers II
Chair: K. Fizazi, FR

Bladder cancer:

- Neoadjuvant and adjuvant chemotherapy (locally advanced disease)
  R. Huddart, UK
- Metastatic disease: Systemic treatment
  R. Huddart, UK

Renal cancer:

- Metastatic renal cancer: Evidence-based treatment
  T. Eisen, UK

17:50 Coffee break

18:20 Tumour board Genito-urinary cancers
K. Fizazi, FR - A. Horwich, UK - T. Eisen, UK - R. Huddart, UK

20:30 Dinner

18 March

8:30 Clinical session Breast cancer I
Chair: G. Viale, IT

Pathology of breast cancer
G. Pruneri, IT
Early systemic treatment I: Neoadjuvant  
O. Pagani, CH

Early systemic treatment I: Neoadjuvant, surgical viewpoint  
W. Gatzemeier, IT

10:00 Clinical session Breast cancer II  
Chair: O. Pagani, CH

Early systemic treatment II: Adjuvant  
G. Curigliano, IT

10:45 Coffee break

Treatment of metastatic breast cancer  
N. Harbeck, DE

Radiotherapy: Key points  
J. Bernier, CH

12:15 Tumour board Breast cancer  
G. Viale, IT - J. Bernier, CH - G. Curigliano, IT - W. Gatzemeier, IT

13:15 Lunch

14:30 Supportive Care Session

Early Antiemetics  
M. Aapro, CH

G CSF and EPO  
M. Aapro, CH

15:00 Sponsored lecture Bone health in advanced cancer patients  
(SPCC lecture by Amgen)  
R. von Moos, CH

15:30 Spotlight session 1 Haematological diseases  
M. Ghielmini, CH

16:30 Coffee break

17:00 Sponsored lecture Management of senior ADULTS with prostate cancer - SIOG guidelines  
(SPCC lecture by Sanofi Oncology)  
J. Fitzpatrick, IE

17:30 Spotlight session 2 Therapeutic management of gliomas  
M. Weller, CH

18:00 Case presentations by participants  
(Genito-urinary cancers and breast cancer)

19:30 Dinner
19 March

8:30 Clinical session Gynaecological cancers
   Chair: J. Vermorken, BE

   - Ovarian cancer
     J.B. Vermorken, BE
   - Cervical and endometrial cancers
     C. Sessa, CH

10:30 Coffee break

11:00 Clinical session Head and neck cancer
   Chair: J. Bernier, CH

   - Prognostic factors and surgical approach
     A. Dietz, DE
   - Radiotherapy
     J. Bernier, CH
   - Systemic therapy
     J.B. Vermorken, BE

13:00 Lunch

14:30 Tumour board Gynaecological cancers
   J.B. Vermorken, BE - C. Sessa, CH

15:00 Tumour board Head and neck cancer
   J.B. Vermorken, BE - A. Dietz, DE - C. Sessa, CH

15:30 Sponsored lecture How to evaluate genomic Classifiers in oncology
   (SPCC lecture by Genomic Health)
   S. Dirnhofer, CH

16:00 Sponsored lecture The importance of the mTOR pathway in Breast Cancer treatment
   (SPCC lecture by Novartis)
   F. André, FR

16:30 Spotlight session 3 Cancer and pregnancy
   N. Pavlidis, CH

17:00 Coffee break

17:30 Case presentations by participants
   (Gynaecological and head and neck cancers)

Dinner

19:30
20 March

8:30 Clinical session Gastro-intestinal tumours I
Chair: E. Van Cutsem, BE

Colon cancer:

Adjuvant and neoadjuvant treatment of colorectal cancer
K.H. Köhne, DE

Systemic treatment in advanced disease
E. Van Cutsem, BE

10:00 Sponsored lecture Metastasectomies in colorectal cancer
(SPCC lecture by Merk)
G.J. Poston, UK

10:30 Coffee break

11:00 Clinical session Gastro-intestinal tumours II
Chair: E. Van Cutsem, BE

Management of rectal cancer (surgery and radiotherapy)
D. Sebag-Montefiore, UK

Systemic treatment in early and advanced gastric cancer
C.H. Köhne, DE

12:30 Tumour board Gastro-intestinal tumours
E. Van Cutsem, BE - D. Sebag-Montefiore, UK - K.H. Köhne, DE

13:30 Lunch

14:30 Sponsored lecture Maintenance treatment in advanced non small cell lung cancer: a new treatment paradigm?
(SPCC lecture by Lilly)
T. Brodowicz, AT

15:00 e-ESO online session on New accomplishments in breast cancer chemoprevention
A. Decensi, Galliera Hospital, Genoa, IT

16:00 Free time

19:30 Dinner

21 March

8:30 Clinical session Lung cancer and mesothelioma I
Chair: R. Stahel, CH

Surgery
W. Weder, CH

Radiotherapy
C. Faivre-Finn, UK
Non-small cell lung cancer systemic therapy
R.A. Stahel, CH

10:30 Coffee break

11:00 Clinical session Lung cancer and mesothelioma II
Chair: R.A. Stahel, CH

Small cell lung cancer
C. Faivre-Finn, UK

Mesothelioma
R.A. Stahel, CH

12:00 Tumour board Lung cancer
R.A. Stahel, CH - W. Weder, CH - C. Faivre-Finn, UK

13:00 Lunch

14:15 Joint medics and nursing session Side effects of systemic treatment and their management

Cardiovascular toxicity
A. Albini, IT

Skin toxicity
S. Segaert, BE

Neurotoxicity
G. Cavaletti, IT

15:30 Joint medics and nursing session Oral therapy: Adherence, compliance and drug interaction
K. Redmond, CH

16:00 Coffee break

16:30 Joint medics and nursing session Palliative care

Pain control
D. Schrijvers, BE

Advanced disease management
A. Hoy, UK

18:00 Learning assessment tests

19:30 Dinner

22 March

8:30 Spotlight session 4 Cancer on unknown primary
N. Pavlidis, GR

9:30 Spotlight session 5 Sarcoma
P. Casali, IT

10:30 Coffee break
ATTENDANCE TO THE MASTERCLASS

Attendance to the masterclass was by application only. Successful applicants were granted free registration and accommodation.

*Application deadline was 1 DECEMBER 2012*

**Ideal Masterclass candidate profile:**
- Age between 30 and 40 years
- At least 2-3 years’ experience in medical oncology or clinical oncology
- Involvement in scientific activities
- Fluency in English

**APPLICATION PROCEDURE:**
Candidates had to fill in the application form ([www.eso.net](http://www.eso.net)) providing:
- Letter describing motivation for attending
- CV with list of publications
- Supporting letter from head of department or mentor
- Clinical case relating to one of the subjects of the Masterclass

**COURSE STATISTICS**

Out of 135 applications 61 Participants were selected. The international faculty encompassed 38 members. 10 Observers from SPCC Members were present throughout the event.

**PARTICIPANTS STATISTICS**

<table>
<thead>
<tr>
<th>SPECIALITY</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Oncology</td>
<td>35</td>
</tr>
<tr>
<td>Clinical Oncology</td>
<td>13</td>
</tr>
<tr>
<td>RT Oncology</td>
<td>2</td>
</tr>
<tr>
<td>Cancer Research</td>
<td>2</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>1</td>
</tr>
<tr>
<td>Others or not Specified</td>
<td>8</td>
</tr>
</tbody>
</table>
### AGE

<table>
<thead>
<tr>
<th>Age</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under 35</td>
<td>30</td>
</tr>
<tr>
<td>35-45</td>
<td>22</td>
</tr>
<tr>
<td>Over 45</td>
<td>3</td>
</tr>
</tbody>
</table>

### COUNTRY

<table>
<thead>
<tr>
<th>Country</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Kingdom</td>
<td>7</td>
</tr>
<tr>
<td>Italy</td>
<td>7</td>
</tr>
<tr>
<td>Switzerland</td>
<td>6</td>
</tr>
<tr>
<td>Germany</td>
<td>4</td>
</tr>
<tr>
<td>Greece</td>
<td>3</td>
</tr>
<tr>
<td>Portugal</td>
<td>3</td>
</tr>
<tr>
<td>Austria</td>
<td>2</td>
</tr>
<tr>
<td>Brazil</td>
<td>2</td>
</tr>
<tr>
<td>Egypt</td>
<td>2</td>
</tr>
<tr>
<td>France</td>
<td>2</td>
</tr>
<tr>
<td>Moldova</td>
<td>2</td>
</tr>
<tr>
<td>Russia</td>
<td>2</td>
</tr>
<tr>
<td>Serbia</td>
<td>2</td>
</tr>
<tr>
<td>South Africa</td>
<td>2</td>
</tr>
<tr>
<td>Spain</td>
<td>2</td>
</tr>
<tr>
<td>USA</td>
<td>2</td>
</tr>
<tr>
<td>Canada</td>
<td>1</td>
</tr>
<tr>
<td>Denmark</td>
<td>1</td>
</tr>
<tr>
<td>Ireland</td>
<td>1</td>
</tr>
<tr>
<td>Lithuania</td>
<td>1</td>
</tr>
<tr>
<td>Poland</td>
<td>1</td>
</tr>
<tr>
<td>Romania</td>
<td>1</td>
</tr>
<tr>
<td>Slovak Republic</td>
<td>1</td>
</tr>
<tr>
<td>Sweden</td>
<td>1</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>1</td>
</tr>
<tr>
<td>Turkey</td>
<td>1</td>
</tr>
<tr>
<td>Zambia</td>
<td>1</td>
</tr>
</tbody>
</table>

### EVALUATION OF THE 11th MASTERCLASS IN CLINICAL ONCOLOGY

<table>
<thead>
<tr>
<th>Evaluation</th>
<th>Scoring (1-4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall rating</td>
<td>3.54</td>
</tr>
<tr>
<td>Achievement of the goals</td>
<td>3.68</td>
</tr>
<tr>
<td>Usefulness of information</td>
<td>3.64</td>
</tr>
<tr>
<td>Evidence-based teaching</td>
<td>3.59</td>
</tr>
<tr>
<td>Interaction (among faculty and participants)</td>
<td>3.51</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Course facilities</td>
<td>3.61</td>
</tr>
<tr>
<td>Course organisation</td>
<td>3.71</td>
</tr>
<tr>
<td><strong>Teaching per topic:</strong></td>
<td></td>
</tr>
<tr>
<td>breast cancer</td>
<td>3.42</td>
</tr>
<tr>
<td>lung cancer</td>
<td>3.46</td>
</tr>
<tr>
<td>genito-urinary cancer</td>
<td>3.42</td>
</tr>
<tr>
<td>gynaecological cancer</td>
<td>3.40</td>
</tr>
<tr>
<td>gastro-intestinal cancer</td>
<td>3.52</td>
</tr>
<tr>
<td>head and neck cancer</td>
<td>3.34</td>
</tr>
<tr>
<td>haematological malignancies</td>
<td>3.52</td>
</tr>
<tr>
<td>supportive/palliative care</td>
<td>3.21</td>
</tr>
<tr>
<td>clinical case presentation</td>
<td>3.48</td>
</tr>
</tbody>
</table>

**Average score speakers MCO 2012: 3.34 (2.52-3.75)**

**SUMMARY:**

Participants appreciated the high level of this educational event and the broad opportunities for informal discussion with the faculty during sessions and beyond. Mediating oncological knowledge and principles in this way of full immersion in modern oncology created a collective spirit of teaching and learning to improving clinical skills and patient care. The evaluation of the participants opinion
(questionnaire focussing on programme objectives, programme organisation, course organisation, facilities, and faculty) indicated that the Masterclass met the needs of the participants on most of the items and highlighted the necessity of such an event. The results of this evaluation will be in particular useful to further improve the upcoming 12th Masterclass which will be held in 2013.

The European School of Oncology (ESO) is an independent organisation. It recognises that the industrial partners are crucial for the delivery of best cancer care and fosters the continuation of the dialogue and identification of synergies. It restrains, however, the influence of marketing and strives to maintain its independence from the sponsors with whom it interacts with a neutral approach. Since its inauguration in 1982, ESO has been promoting cancer education in Europe and abroad. The original idea of the school is to fight against cancer in optimising training and updating competence of physicians and health care workers dealing with cancer patients in providing them with a comprehensive understanding of oncology - covering all aspects from epidemiology, screening, primary and secondary prevention, molecular-biology, diagnostic procedures, interdisciplinary treatment modalities, rehabilitation, palliative care, to psycho-oncological skills and promoting the importance of controlled randomised trials in clinical oncology. ESO’s mission is reflected in its motto "Learning to Care", which stresses the concept of studying and learning and also of caring for the patient in a global sense. By improving the skills of all health professionals dealing with cancer patients, ESO shortens the length of time needed to transfer knowledge from advanced research centres to daily practice, combining advanced technology with humanism in care.

Wolfgang Getzemeier, M.D.
ESO Masterclass Scientific Co-ordinator
11th ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY